AR118898A1 - Dominios variantes para multimerizar proteínas y su separación - Google Patents

Dominios variantes para multimerizar proteínas y su separación

Info

Publication number
AR118898A1
AR118898A1 ARP200101330A ARP200101330A AR118898A1 AR 118898 A1 AR118898 A1 AR 118898A1 AR P200101330 A ARP200101330 A AR P200101330A AR P200101330 A ARP200101330 A AR P200101330A AR 118898 A1 AR118898 A1 AR 118898A1
Authority
AR
Argentina
Prior art keywords
proteins
immunoglobulin
separation
variant domains
multimerizing
Prior art date
Application number
ARP200101330A
Other languages
English (en)
Spanish (es)
Inventor
Kruif Cornelis Adriaan De
Peter Brian Silverman
Richard Bonneau
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of AR118898A1 publication Critical patent/AR118898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ARP200101330A 2019-05-09 2020-05-08 Dominios variantes para multimerizar proteínas y su separación AR118898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09

Publications (1)

Publication Number Publication Date
AR118898A1 true AR118898A1 (es) 2021-11-10

Family

ID=66476558

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101330A AR118898A1 (es) 2019-05-09 2020-05-08 Dominios variantes para multimerizar proteínas y su separación

Country Status (16)

Country Link
US (1) US20210054049A1 (cg-RX-API-DMAC7.html)
EP (1) EP3966238A2 (cg-RX-API-DMAC7.html)
JP (2) JP7760377B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017909A (cg-RX-API-DMAC7.html)
CN (2) CN114702587A (cg-RX-API-DMAC7.html)
AR (1) AR118898A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020268684C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022405A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139402A1 (cg-RX-API-DMAC7.html)
IL (1) IL287928A (cg-RX-API-DMAC7.html)
MA (1) MA55884A (cg-RX-API-DMAC7.html)
MX (1) MX2021013646A (cg-RX-API-DMAC7.html)
PH (1) PH12021552833A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112399PA (cg-RX-API-DMAC7.html)
TW (1) TW202108613A (cg-RX-API-DMAC7.html)
WO (1) WO2020226502A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094318A1 (en) * 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
MX2023007028A (es) * 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
MX2023015461A (es) * 2021-06-17 2024-01-18 Fapon Biotech Inc Inmunoglobulina quimerica.
CN121824747A (zh) 2022-12-27 2026-04-10 美勒斯公司 产生双重特异性蛋白的方法
TW202544033A (zh) 2024-04-15 2025-11-16 荷蘭商美勒斯公司 Cd3結合結構域
TW202608928A (zh) 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體藥物偶聯物
TW202608927A (zh) 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體-藥物偶聯物
WO2026013015A1 (en) 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
EP1554392A4 (en) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF NEW NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH WIDE CROSS-REACTIVITY USING SEQUENTIAL ANTIGEN PANNING OF PHAG DISPLAY LIBRARIES
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-her 항체
TW201212938A (en) * 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP2014511836A (ja) * 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. ヘテロ二量体免疫グロブリン
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
BR112014010257A2 (pt) * 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
WO2013157953A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN104045714B (zh) * 2013-03-14 2019-01-11 南京金斯瑞生物科技有限公司 曲妥珠单抗突变体IgG及其应用
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
SG11201810470XA (en) * 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
WO2017218698A1 (en) * 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
KR20200037250A (ko) 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
TWI917306B (zh) 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
TWI887193B (zh) 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
AU2020268684C1 (en) 2026-04-02
WO2020226502A9 (en) 2022-03-03
AU2025208511A1 (en) 2025-08-14
JP2025120179A (ja) 2025-08-15
CN114702587A (zh) 2022-07-05
BR112021022405A2 (pt) 2022-04-19
SG11202112399PA (en) 2021-12-30
WO2020226502A2 (en) 2020-11-12
CN114430745A (zh) 2022-05-03
US20210054049A1 (en) 2021-02-25
NZ782091A (en) 2025-08-29
AU2020268684B2 (en) 2025-07-03
AU2020268684A1 (en) 2021-12-09
MA55884A (fr) 2022-03-16
KR20220017909A (ko) 2022-02-14
TW202108613A (zh) 2021-03-01
MX2021013646A (es) 2022-01-31
JP2022534674A (ja) 2022-08-03
JP7760377B2 (ja) 2025-10-27
CA3139402A1 (en) 2020-11-12
PH12021552833A1 (en) 2023-01-16
EP3966238A2 (en) 2022-03-16
IL287928A (en) 2022-01-01
WO2020226502A3 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
PH12021552833A1 (en) Variant domains for multimerizing proteins and separation thereof
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX2018009989A (es) Composiciones funcionales derivadas de frijol mungo.
MX389073B (es) Método para producir una proteína de fusión de anticuerpo.
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
MX2025003310A (es) Integracion dirigida de acidos nucleicos
MX2019014576A (es) Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
BR112012025326A2 (pt) "extração seletiva de proteínas de algas de água salgada"
MX2021001129A (es) Metodo de purificacion de antigenos.
AR080942A1 (es) Produccion de proteinas heteromultimericas
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
EA201690651A1 (ru) Содержащие cmp высокобелковые композиции денатурированного сывороточного белка, содержащие их продукты и их применения
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
MX378520B (es) Metodo para extraer proteinas solubles de biomasa de microalgas.
MX2018009331A (es) Metodos para extraer proteinas a partir de un material a base de sangre.
EA201791918A1 (ru) Модификация белков клеток-хозяев
BR112015021785A2 (pt) Promotores de levedura para expressão de proteína
MX2019007316A (es) Eliminacion de acidos nucleicos y fragmentos de los mismos de un material de biomasa.
WO2018120843A9 (zh) 一种三功能分子及其应用
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
MX2020002552A (es) Métodos y composiciones para preparar proteína surfactante d (sp-d).
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
BR112019001605A2 (pt) processo para a preparação de proteína ou peptídeo